This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries. Approximately 100 CAD patients will be randomized to AZD5718 or placebo (treatment duration 28 days).